Registry of Lobbyists
Active
-
Last Updated:
2024-06-01
| Subject matters | Details | Categories |
|---|---|---|
|
Health,
Research and Development
|
Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR.
|
Policies or Program
|
|
Economic Development,
Health,
Internal Trade,
Research and Development
|
Engage government officials regarding domestic manufacturing of seasonal and pandemic flu vaccine.
|
Policies or Program
|
|
Health
|
Engage the government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians.
|
Policies or Program
|
|
Health,
Privacy and Access to Information
|
Engaging Health Canada on the Self-Care Products Initiative as it pertains to plain language labelling and a risk-based approach to regulatory oversight for non prescription drugs.
|
Regulation
|
|
Health,
Internal Trade,
Research and Development
|
Ensure the National Advisory Committee on Immunization has sufficient resources to undertake timely reviews of new vaccines that are made available to the Canadian marketplace.
|
Policies or Program
|
|
Health
|
Input on the work of the Advisory Committee on the Implementation of National Pharmacare, specifically as it relates to access to medicines.
|
Policies or Program
|
|
Health,
Privacy and Access to Information,
Research and Development,
Science and Technology
|
Participation in consultations regarding the Digital Charter and the federal government's plans to overhaul Canada's privacy regime, to enable the use of anonymized health data for new medication research and development.
|
Legislative Proposal, Bill or Resolution
|
|
Health,
International Trade,
Justice and Law Enforcement
|
Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level reimportation legislation.
|
Legislative Proposal, Bill or Resolution
|
|
Health,
Intellectual Property,
Research and Development
|
Reforms to the Patented Medicines Review Board (PMPRB), whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB do not negatively impact access to patented medicines in Canada.
|
Regulation
|
|
Economic Development,
Health,
Research and Development
|
Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors.
|
Policies or Program
|
|
Economic Development,
Health,
Internal Trade,
Justice and Law Enforcement
|
Sharing information with government and Members of Parliament on different models for national pharmacare, specifically as it relates to access to medicines.
|
Policies or Program
|
|
Health
|
The Government of Ontario has passed legislation requiring the public disclosure of payments made to Health Care Providers and Health Care Organizations by the broader health care industry, including pharmaceutical companies, generic manufacturers, and medical device companies. GlaxoSmithKline seeks to advocate for a national approach to disclosure through either the support of similar provincial initiatives, coordinated action through the Federal / Provincial and Territorial meetings of the Ministers of Health, and / or the establishment of national requirements.
|
Policies or Program
|
| Subject matters | Details | Categories |
|---|---|---|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Engage government officials regarding domestic manufacturing of seasonal and pandemic flu vaccine.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Engage the government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Engaging Health Canada on the Self-Care Products Initiative as it pertains to plain language labelling and a risk-based approach to regulatory oversight for non prescription drugs.
|
Regulation
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Ensure the National Advisory Committee on Immunization has sufficient resources to undertake timely reviews of new vaccines that are made available to the Canadian marketplace.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Input on the work of the Advisory Committee on the Implementation of National Pharmacare, specifically as it relates to access to medicines.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Participation in consultations regarding the Digital Charter and the federal government's plans to overhaul Canada's privacy regime, to enable the use of anonymized health data for new medication research and development.
|
Legislative Proposal, Bill or Resolution
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level reimportation legislation.
|
Legislative Proposal, Bill or Resolution
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Reforms to the Patented Medicines Review Board (PMPRB), whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB do not negatively impact access to patented medicines in Canada.
|
Regulation
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Sharing information with government and Members of Parliament on different models for national pharmacare, specifically as it relates to access to medicines.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
The Government of Ontario has passed legislation requiring the public disclosure of payments made to Health Care Providers and Health Care Organizations by the broader health care industry, including pharmaceutical companies, generic manufacturers, and medical device companies. GlaxoSmithKline seeks to advocate for a national approach to disclosure through either the support of similar provincial initiatives, coordinated action through the Federal / Provincial and Territorial meetings of the Ministers of Health, and / or the establishment of national requirements.
|
Policies or Program
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
| Date | DPOH, Position Title | Government Institution | Subject Matters |
|---|---|---|
| 2024-06-25 |
|
Health |
| 2024-02-08 |
|
Research and Development, Economic Development, Health |